NCT04476043

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 209 (actual)
• Sponsor: Incyte Corporation · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).

Conditions

• Hidradenitis Suppurativa
• Acne Inversa

Interventions

Type	Name	Description
DRUG	INCB054707	Oral; Tablet
DRUG	Placebo	Oral; Tablet

Timeline

• Start date: 2020-08-25
• Primary completion: 2021-12-15
• Completion: 2023-08-16
• First posted: 2020-07-17
• Last updated: 2025-08-12
• Results posted: 2023-01-26

Locations

40 sites across 6 countries: United States, Canada, France, Germany, Poland, Spain

Regulatory

• FDA-regulated drug study